SEARCHING ALGORITHM OF CAUSES OF THROMBOCYTOPENIA
Abstract
In practice are often observed patients with thrombocytopenia requiring the correction by transfusion of platelet. However, the cause of the platelet's reduction is not always obvious, what needs to be clarified. In this article, we described the main pathogenic types of thrombocytopenia. We present an algorithm that will help the physicians to understand the causes of thrombocytopenia and to determine the necessity of platelet transfusions depending on the clinical settings and on the type of thrombocytopenia. Absolute indications for platelet transfusions are surgeries and life-threatening bleeding, while the relative indications are thrombocytopenia due to consumption.
About the Authors
I. A. Pashkova
Krasnodar regional hospital № 1
Russian Federation
Russian Federation
I. V. Gilevich
Krasnodar regional hospital № 1
Russian Federation
Russian Federation
N. V. Mineeva
Krasnodar regional hospital № 1
Russian Federation
Russian Federation
References
1. Баркаган З.С. Патология тромбоцитарного гемостаза // Руководство по гематологии. - Москва, 2005. - С. 416.
2. Бессмельцев С.С. Идиопатическая тромбоцитопеническая пурпура // Гематология: новейший справочник. - Москва, 2004. - С. 928.
3. Мамаев Н.Н. Тромбоцитопении // Гематология: руководство для врачей. - Санкт-Петербург, 2008. - С. 543.
4. Масчан А.А., Румянцев А.Г. Стимуляция продукции тромбоцитов: новый подход к лечению хронической иммунной тромбоцитопенической пурпуры // Онкогематология. - 2009. -№ 1. - С. 51-56.
5. Птушкин В.В., Миненко С.В., Биячуев Э.Р., Пшонкин А.В., Шубина А.В. Лечение больных с резистентной иммунной тромбоцитопенией: обзор литературы и клинические наблюдения // Онкогематология. - 2011. - № 1. - С. 56-63.
6. Филатов Л.Б. Тромботические микроангиопатии // Клиническая онкогематология. - 2008. - № 4. - С. 366-376.
7. Armstrong B. Benefits and risks of transfusion // ISBT science series. - 2008. - Vol. 3. № 2. - P. 216-231.
8. Aster R.H., Curtis B.R., McFarland J.G., Bougie D.W. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management // J. thromb. haemost. - 2009. - Vol. 7. № 6. -P. 911-918.
9. Beck O.N. Thrombocytopenia. Chapter 11 // Diagnostic hematology. - London, 2009. - P. 518.
10. Cines D.B., Blanchette V.S. Immune thrombocytopenic purpura // Engl. j. med. - 2002. - Vol. 346. № 13. -P. 995-1008.
11. Cortelazzo S., Finazzi G., Buelli M., Molteni A., Viero P., Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopeniapurpura // Blood. - 1991. - Vol. 77. № 1. - P. 31-33.
12. Furlan M., Robles R., Galbusera M., Remuzzi G., Kyrle P.A., Brenner B., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome // N. engl. j. med. - 1998. - Vol. 339. № 22. -P. 1578-1584.
13. Gauer R.L., Braun M.M. Thrombocytopenia // Am. fam. physician. - 2012. - Vol. 85. № 6. - P. 612-622.
14. Godeau B., Chevret S., Varet B., Lefrère F., Zini J.M., Bassompierre F., et al. French ATIP Study Group. Intravenous immunoglobulin in high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized, multicentre trial // Lancet. - 2002. - Vol. 359. № 9300. - P. 23-29.
15. Hillman R.S., Ault K.A., Rinder H. Thrombocytopenia. Chapter 30 // Hematology in clinical practice: a guide to diagnosis and management. - New York, 2005. - P. 512.
16. Kiefel V., Santoso S., Mueller-Eckhardt C. Serological, biochemical, and molecular aspects of platelet autoantigens // Sem. hematol. - 1992. - Vol. 29. № 1. - P. 26-33.
17. Lotta L.A., Garagiola I., Palla R., Cairo A., Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura // Hum. mutat. - 2010. - Vol. 31. № 1. - P. 11-19.
18. Provan D., Stasi R., Newland A.C., Blanchette V.S., Bolton-Maggs P., Bussel J.B. International consensus report on the investigation and management of primary immune thrombocytopenia // Blood. - 2010. - Vol. 115. № 2. - P. 168-186.
19. Puyo C.A. Thrombocytopenia // Inter. anesthesiol. clin. -2001. - Vol. 39. № 1. - P. 17-34.
20. Schlenke P., Sibrowski W. Cross-sectional guidelines for therapy with blood components and plasma derivatives // Transfus. med. hemotherapy. - 2009. - Vol. 36. № 6. -P. 345-492.
21. Schoonen M., Kucera G., Coalson J., Lin Li, Rutstein M., Mowat F., Fryzek J., Kaye J.A. Epidemiology of immune thrombocytopenic purpura in the general practice research database // Br. j. haematol. - 2009. - Vol. 145. № 2. - P. 235-244.
22. Slichter S.J. Relationship between platelet count and bleeding risk in thrombocytopenic patients // Transfus. med. rev. -2004. - Vol. 18. № 3. - P. 153-167.
23. Terrell D.R., Williams L.A., Vesely S.K., Lämmle B., Hovinga J.A., George J.N. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency // J. thromb. haemost. - 2005. - Vol. 3. № 7. - P. 1432-1436.
24. Tsai H.M., Li A., Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura // Clin. lab. - 2001. - Vol. 47. № 7. - P. 387-392.
25. Van den Bemt P.M., Meyboom R.H., Egberts A.C. Drug-induced immune thrombocytopenia // Drug. saf. - 2004. - Vol. 27. № 15. - P. 1243-1252.
26. Veneri D., Franchini M., Randon F., Nichele I., Pizzolo G, Ambrosetti A. Thrombocytopenia: a clinical point of view // Blood transfus. - 2009. - Vol. 7. № 2. - P. 75-85.
Review
For citations:
Pashkova I.A., Gilevich I.V., Mineeva N.V. SEARCHING ALGORITHM OF CAUSES OF THROMBOCYTOPENIA. Kuban Scientific Medical Bulletin. 2014;(3):93-99. (In Russ.)
Views:
251
Email this article 